anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
A novel pharmaceutical composition for treating ALS is provided comprising as the active ingredient an anti-EphA4 antibody that can bind to EphA4 and enhance the cleavage of EphA4. A pharmaceutical composition for treating ALS comprising an anti-EphA4 antibody is provided, wherein the anti-EphA4 antibody comprises a heavy chain comprising a heavy chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO. 44, a heavy chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO. 27, and a heavy chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO. 28, and a light chain comprising a light chain CDR1 consisting of the amino acid sequence shown in SEQ ID NO. 29, a light chain CDR2 consisting of the amino acid sequence shown in SEQ ID NO. 30, and a light chain CDR3 consisting of the amino acid sequence shown in SEQ ID NO. 31.
When benzodiazepines or other CNS depressants are used with Sufentanil Citrate Injection, pulmonary arterial pressure may be decreased. This fact should be considered by those who conduct diagnostic and surgical procedures where interpretation of pulmonary arterial pressure measurements might determine final management of the patient. When high dose or anesthetic dosages of Sufentanil Citrate Injection are employed, even relatively small dosages of diazepam may cause cardiovascular depression. 

When Sufentanil Citrate Injection is used with CNS depressants, hypotension can occur. If it occurs, consider the possibility of hypovolemia and manage with appropriate parenteral fluid therapy. When operative conditions permit, consider repositioning the patient to improve venous return to the heart. Exercise care in moving and repositioning of patients because of the possibility of orthostatic hypotension. If volume expansion with fluids plus other countermeasures do not correct hypotension, consider administration of pressor agents other than epinephrine. Epinephrine may paradoxically decrease blood pressure in patients treated with a neuroleptic that blocks alpha adrenergic activity. 

Profound sedation, respiratory depression, coma, and death may result from the concomitant use of Sufentanil Citrate Injection with benzodiazepines or other CNS depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol). 

If the decision is made to manage postoperative pain with Sufentanil Citrate Injection concomitantly with a benzodiazepine or other CNS depressant, start dosing with the lowest effective dosage and titrate based on clinical response. Follow patients closely for signs and symptoms of respiratory depression, sedation, and hypotension. Fluids or other measures to counter hypotension should be available [see Drug Interactions (7)].
The invention provides a Coxsackievirus A16 type (Coxsackievirus A16) virus strain, application, a vaccine and a preparation method thereof. In the coxsackievirus A16 type virus strain provided by the invention, the preservation number of the virus strain is CGMCC No. 6954. The CA16 virus strain provided by the invention has the following advantages: the vaccine has strong virulence, can be used for evaluating a CA16 vaccine and can also be used for researching an infection mechanism of a CA16 virus. The establishment method for the Coxsackie virus A16 type infected animal model can provide a stable animal model, and provides a foundation for research of Coxsackie virus A16 type vaccine, screening of antiviral drugs and research of CA16 virus infection mechanism. Vaccines prepared from the CA16 strain of the invention have potent immunological activity.
FIELD: cosmetology, particularly, prophylactic agent for body and face skin care and for its cleansing from dirt. SUBSTANCE: remedy contains the following ingredients, mas. %: powder of air-dry oat straw and oat flour, 25-75 : 75-25, respectively. Proposed remedy is recommended for body and face skin care for persons constantly living or working in zones with increased contamination. EFFECT: higher efficiency. 3 ex
For the first 6 months of the study, subjects will take Placebo (4 capsules x BID, p.o.) before meals. From six months to 12 months from the beginning of the study, subjects will take Placebo (4 capsules x BID) and participate in a weekly non-aerobic yoga program (Attendance at 2 classes of 1 hour duration or 1 hr SecureVideo Live videoconference remote classes for subject who become proficient\] and 2 home practices of 30 minute duration per week).
BACKGROUND: Cohen syndrome (CS) is a rare autosomal recessive inherited condition characterized by pathological changes affecting multiple systems. The extensive clinical variability associated with CS poses a significant diagnostic challenge. Additionally, there is limited documentation on the co-occurrence of CS with psychiatric symptoms.
CASE REPORT: We report a case of a 30-year-old patient exhibiting characteristic physical features and psychiatric symptoms. Whole exome sequencing identified two heterozygous variants, a nonsense variation c.4336 C > T and a missense mutation c.4729G > A. Integrating clinical manifestations with genetic test results, we established the diagnosis of CS combined with psychiatric symptoms.
CONCLUSIONS: This case introduces a novel missense variant as a candidate in the expanding array of VPS13B pathogenic variants. Its clinical significance remains unknown, and further investigation may broaden the spectrum of pathogenic variants associated with the VPS13B gene. Early diagnosis of CS is crucial for the prognosis of young children and holds significant importance for their families.
Patients receive placebo PO BID on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients with disease progression may crossover to Arm I.
There are disclosed protein condensation inhibitors which are useful in the treatment of phase transition disease states associated with the phase transition of proteins from a soluble to a condensed state. Methods of identifying compounds for their ability to function as protein condensation inhibitors, as well as the use of such protein condensation inhibitors to treat phase transition disease states, are also disclosed. In one embodiment, a method of identifying compounds comprises assaying the compound in an aqueous protein solution to determine whether the sign of δE is positive. In this method, the assaying may include the steps of measuring a change in phase separation temperature and determining whether protein condensation occurs upon raising or lowering the temperature of the aqueous protein solution. Preferably, the aqueous protein solution comprises a protein associated with a phase transition disease state, such as sickle hemoglobin. In another embodiment, a method of identifying compounds involves assaying the compound in at least two distinct aqueous protein solutions for its ability to prevent or delay a temperature dependent phase transition to a condensed state in each of the distinct aqueous protein solutions. Examples of suitable proteins for the distinct aqueous protein solutions include lysozyme and sickle hemoglobin.
The invention relates to a lotus seed pill for blood stasis dissolving and pain relieving. The pill is prepared through reasonable compatibility of carefully selected Chinese herbal medicines. Lumbago occurs throughout the year and has high incidence, it is reported abroad that 80% of people in the world suffer from lumbago and backache, and lumbago is one of the most common diseases in traditional Chinese medicine outpatient department, and can be well treated through traditional Chinese medicine. The lumbago is related to climate change, and the lumbago is unrelated to climate change. The lumbago is aggravated by fatigue and is weakened by rest. The lumbago influences functional activities comprising waist twisting and pitching. The lumbago is fixed, radiates to other positions, and causes stiff lumbar vertebra, lumbago and backache, lumbocrural pain, lumbosacral pain, and lumbago induced lateral lower abdomen. The lotus seed pill for blood stasis dissolving and pain relieving has the efficacies of blood circulation promoting, blood enriching, nourishing, vacuity supplementing ,qi moving, stagnation removing, blood stasis dissolving and pain relieving, and is especially suitable for patients with psoas fibrositis, ankylosing spondylitis, lumbar osteosis, lumbar intervertebral disc pathologies, lumbar muscle strains and other waist pathologies, and some visceral diseases with lumbago as the main symptom.
PURPOSE: To obtain a bathing agent composition having high ameliorating effect for various symptoms involved in skin pruritus or eczema without staining bathing water and bathtub, also safe to the skin, by formulating an extract obtained from seeds of Avena sativa Linne using a specific solvent. CONSTITUTION: This bathing agent composition contains, as active ingredient, an extract obtained by extracting seeds of (Avena sativa Linne) with water and/or a water-soluble organic solvent (pref. at least one kind selected from ethanol, butanol, propylene glycol and 1,3-butylene glycol). The extract is pref. the aqueous fraction obtained by fractionation with water plus ethyl acetate. Besides, this composition contains pref. an inorganic salt (e.g. sodium sulfate, sodium carbonate), carbon dioxide or a carbon dioxide-generating material. It is preferable that the amount of the extract to be formulated in this composition be such a level, per 150-200L of bathing water, as to be obtained from 0.001-1000g of raw seed powder of Avena sativa Linne.
The invention discloses a pouzolzia extract, a preparation method thereof, and an application thereof. According to the invention, for a first time, four compounds are separated and identified from subsiding swelling and pus removing effective parts of pouzolzia. A water extract prepared from pouzolzia and a chloroform or n-butyl alcohol extracted part thereof provide subsiding swelling and pus removing effects. The chloroform extracted part contains friedelin. The n-butyl alcohol extracted part contains kaempferol-7-O-alpha-L-pyran rhamnoside, quercetin-7-O-alpha-L-pyran rhamnoside, quercetin-3, and 7-O-alpha-L-2-pyran rhamnoside. The extract provided by the invention provides good subsiding swelling, pus removing, inflammation resisting, and pain relieving effects. The extract can be used for preparing subsiding swelling and pus removing medicines.
PURPOSE:To provide a carrier easy to immobilize antigen or antibody, and to provide an immunological diagnostic high in refractive index, thus enabling assays in high sensitivity by light scattering analysis or integrating-sphere turbidimetry. CONSTITUTION:The objective carrier for immunological diagnostics comprising polymer particles prepared by polymerization, using a radical polymerization initiator in an aqueous medium, of monomer component composed of (A) 5-99.9 (pref. 30-99.9) wt.% of a styrene derivative of the formula (R is H or methyl; X is F, Cl, Br, I or methyl; k is 1 or 2; m and n are each O or 1), e.g. m-[(p- chlorophenylthio)methyl]styrene and (B) 0.1-95 pref. 0.1-70) wt.% of a vinyl compound, styrene, sodium p-styrenesulfonate and/or divinylbenzene. The other objective immunological diagnostic consisting of an aqueous dispersion of immobilized antigen or immobilized antibody by immobilizing an antigen or antibody on the above carrier. The average particle diameter of the carrier is pref. 0.02-20mum (esp. 0.05-1mum).
An aqueous ink composition for inkjet which can suppress fading and discoloration of printed images on the surface of solid preparations such as pharmaceuticals and foods, a method for suppressing fading of printed images on solid preparations, and a solid preparation are provided. An aqueous ink composition for inkjet contains an edible lake pigment and a fading inhibitor. The lake pigment contains a specific lake pigment containing a dye containing at least 1 selected from the group consisting of red No. 2, red No. 3, red No. 40, red No. 102, yellow No. 4, yellow No. 5, blue No. 1 and blue No. 2. The fading inhibitor contains at least 1 kind selected from the group consisting of monosaccharides, disaccharides, dextrins, and sugar alcohols. The content of the fading inhibitor is 50% by mass or less with respect to the total mass of the aqueous ink composition.
BACKGROUND: Myofascial pelvic pain (MFPP), which is identified by tender points in the pelvic floor musculature, is a prevalent source of chronic pelvic pain in women. It may lead to physical and mental exhaustion, reproductive concerns, and coping difficulties in daily life and work than the disease itself. Pain-related cognitive processes can affect pain relief and quality of life. Kinesiophobia, self-efficacy and pain catastrophizing are frequently treated as mediators between pain and its related consequences. Greater kinesiophobia and pain catastrophizing have been shown to be associated with adverse functional outcomes, while higher self-efficacy has been related with improved quality of life. Regarding MFPP in females of childbearing age, it remains unclear whether the effects of kinesiophobia, self-efficacy and pain catastrophizing on daily interference are direct or indirect; the influence on each variable is, therefore, not entirely evident.
AIM: The present study aimed to evaluate the relationship between pain and daily interference in reproductive-age women with MFPP through kinesiophobia, self-efficacy and pain catastrophizing, as well as to identify areas for future investigation and intervention based on the data collected from this population.
METHODS: This is a multi-center cross-sectional study. The study was conducted from November 15, 2022 to November 10, 2023, 202 reproductive-age women with MFPP were recruited from 14 hospitals in ten provinces of China. The demographic variables, Brief Pain Inventory, Tampa Scale of Kinesiophobia, Pain Self-Efficacy Questionnaire, and Pain Catastrophizing Scale were used to measure the participants' related information. The data was described and analyzed using Descriptive analyses, Pearson correlation analysis, and Serial mediation modeling.
RESULTS: Pain not only had a direct positive impact (B = 0.575; SE   =   0.081; 95%CI: LL = 0.415, UL = 0.735) on daily interference, but also had an indirect impact on daily interference through the independent mediating role of pain catastrophizing (B = 0.088; SE  =  0.028; 95%CI: LL = 0.038, UL = 0.148), the chain mediating of kinesiophobia and catastrophizing (B = 0.057; SE  =   0.019; 95%CI: LL = 0.024, UL = 0.098), and the four-stage serial mediating of kinesiophobia, self-efficacy and catastrophizing (B = 0.013; SE   =  0.006; 95%CI: LL = 0.003, UL = 0.027). The proposed serial mediation model showed a good fit with the collected data.
CONCLUSION: The findings illustrate the significance of addressing pain catastrophizing and kinesiophobia (especially catastrophizing), and increasing self-efficacy in pain therapy, and suggest that functional recovery be integrated into pain therapy for reproductive-age women suffering from MFPP.
An isolated nucleic acid comprising a nucleotide sequence encoding a polypeptide of SEQ ID NO. 3. The polypeptide of SEQ ID NO 3 specifically binds to stage specific embryonic antigen 4(SSEA 4). Also disclosed are recombinant cells comprising the above isolated nucleic acids, viral vectors comprising the above isolated nucleic acids, and isolated polypeptides comprising the sequence of SEQ ID NO. 3. Also provided is a Chimeric Antigen Receptor (CAR) comprising a single chain Fv having the sequence of SEQ ID NO:3 and specifically binding to SSEA 4. Further, a method for treating a tumor by: transducing T cells of a subject having a tumor expressing SSEA4 in vitro with a vector encoding a CAR, expanding the transduced T cells, and injecting the expanded transduced T cells into the subject, thereby generating an anti-tumor T cell response.
Sipuleucel-T with the concentration of 5 μg/mL PA2024 in a cell suspension of 1 x 10\^7 PBMCs per mL. Subjects received infusion of sipuleucel-T, at 2-week intervals, for a total of 3 infusions.
Patients are treated in this single-arm trial with oral crizotinib 250 mg b.i.d.. Treatment dose will be adjusted according to the protocol if indicated. Treatment will be conducted until disease progression or beyond disease progression according to the protocol if clinically indicated.
The invention discloses a healthcare capsule capable of resisting fatigue and improving sexual functions. Components of the capsule are different from components of traditional related capsules. The components of the capsule provided by the invention are free of artificial chemicals and medium in price and only contain five kinds of materials, so that the capsule is cheap and totally free of side and toxic effects. The form used as a medicine of the main components is an extract product thereof. The form used as a medicine of thermal sensitive natural animal medicine components is superfine freeze-dried powder thereof. Compatibility of each of the components has synergistic effects. Animal functional tests show that the capsule has good function of relieving physical fatigue and results of a test of improving animal sexual functions are positive. The capsule comprises 15-45% of an American ginseng alcohol-soluble extract product, 5-25% of sheep testicular freeze-dried powder, 5-25% of an acanthopanax root aqueous extract product, 5-25% of a kudzu vine root aqueous extract product, 5-20% of fructus hippophae powder and 5-15% of an accessory material that is medicinal starch or medicinal dextrin.
1. Technical Result Increase in treatment efficiency.           2. Essence A pharmaceutical composition for each part by weight of paracetamol comprises from 1 to 4 by volume ethanol and from 1 to 5 by volume of a polyethylene glycol; it is substantially anhydrous and forms a clear solution for injection with 4-10 parts by volume of water.          3. Field of Application Medicine.               Tables: 1
Participants with Relapsed/Refractory (R/R) FL will receive obinutuzumab 400 milligrams (mg) intravenous (IV) infusion on Days 1 and 8 of Cycle 1 and every 3 weeks on Day 1 of subsequent cycles (for 68 cycles) in the induction period; Prednisone 100 mg/day orally on Days 15, doxorubicin 50 milligrams per square-meter (mg/m\^2), vincristine 1.4 mg/m\^2 capped at 2 mg, and cyclophosphamide 750 mg/m\^2 IV infusion every 3 weeks on Day 1 of each cycle for 68 cycles in the induction period. 12 weeks following last infusion, participants with CR or PR will be eligible to receive 400 mg obinutuzumab IV infusion once every 3 months for 2 years or until disease progression in the maintenance period.
There is limited literature on current human papillomavirus (HPV) vaccination in the Asia-Pacific region. This integrative literature review was conducted to describe HPV vaccination programs in Hong Kong, Indonesia, Japan, South Korea, Malaysia, the Philippines, Singapore, Taiwan, Thailand, and Vietnam. Program descriptions, recommendations, f unding, and coverage data were extracted. Twenty-five citations were included. As of 2022, eight of the 10 areas of interest include HPV in their national immunization program (NIP) for school-aged girls; full implementation in Indonesia is expected in 2023 whereas Vietnam's NIP does not include HPV. Singapore also includes HPV vaccination for women (18-26 years). None of the HPV vaccination programs include males. In most areas (n = 7), programs include only one vaccine option. While female HPV NIPs are present in the Asia-Pacific region, opportunities remain to strengthen NIPs in broader populations (e.g., males, catch-up cohorts) to expand public health impact and provide gender equity in HPV vaccination.
Bromocriptine mesylate, USP is an ergot derivative with potent dopamine receptor agonist activity. Each bromocriptine mesylate capsule for oral administration contains 5 mg bromocriptine (as the mesylate). Bromocriptine mesylate is chemically designated as 2-Bromoergocryptine monomethanesulfonate (salt).

The structural formula is:

The active ingredient in bromocriptine mesylate capsules, USP is bromocriptine mesylate, USP. The inactive ingredients are as follows: anhydrous lactose, black iron oxide, D&C Yellow No. 10 Aluminum Lake, gelatin, magnesium stearate, maleic acid, pregelatinized starch (corn), red iron oxide, sodium lauryl sulfate, titanium dioxide and yellow iron oxide.

In addition, the black imprinting ink contains black iron oxide, D&C Yellow No. 10 Aluminum Lake, FD&C Blue No. 1 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, n-butyl alcohol, propylene glycol, SDA 3A alcohol, SD-45 alcohol and shellac glaze.
The treatment regimen for Docetaxel (D) will be followed for this arm. In addition, on Days 1 and 8 of the 21 day cycle, patients will receive Plinabulin (P) administered via IV infusion over 60 minutes. On Day 1, the infusion begins 2 hours from the starting time of docetaxel infusion, i.e, approximately 60 minutes from the end of docetaxel infusion. On Day 8, patients must be given an anti-emetic prophylactically before the plinabulin infusion. If emesis persists after Day 8, with a grade \>1, plinabulin will be reduced to 20 mg/m2. Patients from the DP Arm who stop treatment with docetaxel due to toxicity or another medically acceptable reason, may continue treatment with plinabulin alone as previously described.
The present invention provides a cosmetic composition. According to the present invention, a mixed fermented liquid, which is a mixture of a fermented sprout liquid and a fermented ginseng fruit liquid, is matured and then a stabilizer is added to the mixed fermented liquid to produce the cosmetic composition. The cosmetic composition is produced by mixing a matured mixed liquid and 10-20 parts by weight of honey as a stabilizer. The matured mixed liquid is made by mixing 5-20 parts by weight of the fermented sprout liquid and 10-40 parts by weight of the fermented ginseng fruit liquid. The cosmetic composition is fermented by lactic acid bacteria. [Reference numerals] (AA) Fermented sprout liquid (Sugar fermentation); (BB) Fermented ginseng fruit liquid (Lactic acid fermentation); (CC) Age a mixed fermented liquid; (DD) Add a stabilizer
The Mézières treatment has 3 postures that could be adapted to each patient, depending on his/her needs to correct variations in the dorsal curve and promote diaphragmatic breathing. The first objective was to recover extensibility of the hypertonic muscle groups and, in particular, those in the low back muscular chain. The time of tratment will be of 1 hour, two times a week, during 5 weeks.
This study aims to determine whether the gait patterns in these subjects differ in predictable and quantifiable ways from those of age- and sex-matched healthy controls. This will be conducted by asking 40 Parkinsonian disorder subjects and 40 age-matched healthy control subjects to walk 9 trials over an 18 ft walkway embedded with pressure sensors at baseline, self-selected slower and faster speeds. In addition, the protocol aims to investigate whether clusters of gait patterns can be identified within subgroups of individuals with parkinsonian disorders with varying co-morbidities or treatment conditions as well as patients with ataxia syndromes. For this aim an additional 20 Parkinsonian disorder subjects need to be recruited. Patients with parkinsonism as defined by UK PD Brain Bank Criteria (n=60), subjects with acquired or inherited ataxic syndromes (n=10) and age- and sex matched controls (n=40) will be recruited. There is an optional second visit in the protocol during which approximately 20 subjects with Parkinsonian disorders, who are willing to come off antiparkinson medication and if applicable, off both medication and deep brain stimulation, are asked to walk an additional 9 trials.